{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-23-000010","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.607964+00:00","generated_at":"2026-06-17T09:50:55.335116+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lisata Therapeutics reports FY2022 financial results and provides business update","bullets":["Net loss for FY2022 was $54.2 million, including $30.4 million non-routine merger-related IPR&D expense.","Cash, cash equivalents and marketable securities totaled $69.2 million as of December 31, 2022.","LSTA1 Phase 2b ASCEND study in pancreatic cancer is ongoing; basket trial in other solid tumors planned for H1 2023.","HONEDRA for critical limb ischemia is in pre-consultation with Japan's PMDA; partner search continues.","XOWNA development suspended; LSTA201 proof-of-concept study did not show consistent kidney function improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-23-000010","json":"https://secwatch.observer/filing/0000320017-23-000010.json","markdown":"https://secwatch.observer/filing/0000320017-23-000010.md","text":"https://secwatch.observer/filing/0000320017-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000010/0000320017-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000010/clbs-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:50:55.335116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8c2dbda41c459f50791572c27163ef0236205e4","claim":"LISATA THERAPEUTICS, INC. reported financial results for three and twelve months ended December 31, 2022.","evidence_excerpt":"Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, NJ (March 30, 2023) – Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three and twelve months ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000010/0000320017-23-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and twelve months ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}